超越 NT-proBNP：心力衰竭和心肌病心房颤动的循环蛋白生物标志物。

IF 5.8 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Canadian Journal of Cardiology Pub Date : 2024-11-07 DOI:10.1016/j.cjca.2024.11.003

Saif Dababneh, Filip Van Petegem, Zachary Laksman

{"title":"超越 NT-proBNP：心力衰竭和心肌病心房颤动的循环蛋白生物标志物。","authors":"Saif Dababneh, Filip Van Petegem, Zachary Laksman","doi":"10.1016/j.cjca.2024.11.003","DOIUrl":null,"url":null,"abstract":"Atrial fibrillation (AF) is largely co-morbid with heart failure (HF), worsening prognosis in patients with ventricular dysfunction. Treating AF through ablation can improve outcomes and reduce the transition to end-stage HF, highlighting the importance of early recognition in patients with ventricular dysfunction. Circulating NT-proBNP is a well-known biomarker for AF in patients with ventricular dysfunction, however, large individual variability limits its predictive power and therefore utility. With the rise of high-throughput proteomics in the era of precision medicine, novel and stable biomarkers may be identified with the potential to improve risk stratification, detection, and management.","PeriodicalId":9555,"journal":{"name":"Canadian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":5.8000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Beyond NT-proBNP: Circulating Protein Biomarkers for Atrial Fibrillation in Heart Failure and Cardiomyopathy.\",\"authors\":\"Saif Dababneh, Filip Van Petegem, Zachary Laksman\",\"doi\":\"10.1016/j.cjca.2024.11.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Atrial fibrillation (AF) is largely co-morbid with heart failure (HF), worsening prognosis in patients with ventricular dysfunction. Treating AF through ablation can improve outcomes and reduce the transition to end-stage HF, highlighting the importance of early recognition in patients with ventricular dysfunction. Circulating NT-proBNP is a well-known biomarker for AF in patients with ventricular dysfunction, however, large individual variability limits its predictive power and therefore utility. With the rise of high-throughput proteomics in the era of precision medicine, novel and stable biomarkers may be identified with the potential to improve risk stratification, detection, and management.\",\"PeriodicalId\":9555,\"journal\":{\"name\":\"Canadian Journal of Cardiology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.8000,\"publicationDate\":\"2024-11-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cjca.2024.11.003\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cjca.2024.11.003","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

心房颤动（房颤）在很大程度上与心力衰竭（HF）并存，使心室功能障碍患者的预后恶化。通过消融治疗心房颤动可改善预后并减少向终末期心力衰竭的转变，这突出了早期识别心室功能障碍患者的重要性。循环中的 NT-proBNP 是众所周知的心室功能障碍患者房颤的生物标志物，然而，个体差异大限制了其预测能力，因此也限制了其效用。随着高通量蛋白质组学在精准医疗时代的兴起，新型稳定的生物标志物可能会被发现，从而有可能改善风险分层、检测和管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Beyond NT-proBNP: Circulating Protein Biomarkers for Atrial Fibrillation in Heart Failure and Cardiomyopathy.

Atrial fibrillation (AF) is largely co-morbid with heart failure (HF), worsening prognosis in patients with ventricular dysfunction. Treating AF through ablation can improve outcomes and reduce the transition to end-stage HF, highlighting the importance of early recognition in patients with ventricular dysfunction. Circulating NT-proBNP is a well-known biomarker for AF in patients with ventricular dysfunction, however, large individual variability limits its predictive power and therefore utility. With the rise of high-throughput proteomics in the era of precision medicine, novel and stable biomarkers may be identified with the potential to improve risk stratification, detection, and management.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Canadian Journal of Cardiology 医学-心血管系统

CiteScore

9.20

自引率

8.10%

发文量

546

审稿时长

32 days

期刊介绍： The Canadian Journal of Cardiology (CJC) is the official journal of the Canadian Cardiovascular Society (CCS). The CJC is a vehicle for the international dissemination of new knowledge in cardiology and cardiovascular science, particularly serving as the major venue for Canadian cardiovascular medicine.